Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.

Orphanet J Rare Dis · 2018 · PMC6236936 · PMID 30428897

Europe PMC DOI

hedged sentence

0.6590

closest p · 13.2× alpha

0.6590

boldest claim

The sentences

showed a trendp = 0.659not close (p > 0.1)

In the low-dose group, the rate of disease progression showed a trend towards decrease after treatment (63% before vs. 43% at 12 months [ p = 0.659] vs. 44% at 24 months [ p = 0.637]) (Fig. 3b ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.